Search all content on GOV.UK

Did you mean Abilify?

• Aripiprazole (Abilify and generic brands): risk of pathological gambling

  Healthcare professionals prescribing aripiprazole are reminded to be alert to the risk of addictive gambling and other impulse control disorders. Healthcare professionals should advise patients, their families and friends to be alert to these risks.

  • Updated: 18 December 2023
• Antipsychotic medicines
  • Updated: 25 August 2005
• Class 3 Medicines Recall: Aspar Pharmaceuticals Ltd, Ibuprofen 200mg Tablets, Ibucalm 200mg tablets, EL(26)A/07

  Aspar Pharmaceuticals Ltd is recalling specific batches distributed in Aspar, Almus and Numark livery. The batches are being recalled as a precautionary measure following findings of foil perforations in some blisters.

  • Updated: 4 February 2026
• Access, new active substance and biosimilar work sharing initiatives

  Information on applying for New Active Substance Work Sharing Initiative (NASWSI) and Biosimilar Work Sharing Initiative (BSWSI) assessments and list of approved products.

  • Updated: 30 January 2026
• Clinical platform trials for coronavirus (COVID-19) treatments

  Past and current clinical trials into therapeutic and antiviral treatments for COVID-19, how to take part, and which treatments have proven to be effective.

  • Updated: 31 March 2023
• Aripiprazole (Abilify): reminder on known risk of gambling disorder

  The MHRA has reminded healthcare professionals prescribing aripiprazole to be alert to the known risk of patients developing addictive gambling, following a rise in the number of reports received in 2023

  • Updated: 18 December 2023
• Check drug analysis profiles (iDAPs)

  Check what side effects people have reported when they have taken a medicine.
• Evaluation of medicines to prevent COVID-19

  How we evaluated pre-exposure prophylactic (preventative) treatments for COVID-19.

  • Updated: 31 March 2023
• Class 3 Medicines Recall: Zambon SpA, Emylif 50mg orodispersible film, EL(25)A/47

  Zambon SpA is recalling an affected batch as a precautionary measure due to out of specification results for unknown impurities during ongoing stability testing.

  • Updated: 10 November 2025
• MHRA approves inavolisib for the treatment of breast cancer

  The MHRA has today, 26 November 2025, approved inavolisib (Itovebi) for the treatment of adults with a type of breast cancer called HR-positive

  • Updated: 26 November 2025